# LGND catalysts: LIGAND PHARMACEUTICALS INC PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/lgnd/catalysts

> LIGAND PHARMACEUTICALS INC (LGND) has 2 upcoming catalysts. The next is the ZTALMY (ganaxolone) trial start, 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, year only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for LGND?

LIGAND PHARMACEUTICALS INC (LGND) has 2 upcoming catalysts. The next is the ZTALMY (ganaxolone) trial start, 2027. Press release filed with the SEC (EX-99): "•On October 26, 2026, Immedica announced that it will advance the development of intravenous (IV) ganaxolone for the treatment of refractory status epilepticus (RSE) and plans to initiate a new phase 3 clinical study in 2027." [Calendar and source filings](https://sec-api.dev/companies/lgnd/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0000886163-26-000058, https://www.sec.gov/Archives/edgar/data/886163/000088616326000058/q32026earningsrelease_ex991.htm (retrieved 2026-11-12). Last confirmed 2026-10-30. Cite: https://sec-api.dev/companies/lgnd/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | LIGAND PHARMACEUTICALS INC |
| Ticker | LGND (Nasdaq) |
| SEC CIK | 886163 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/lgnd |

## Cash runway

Cash $447.4M as of 2026-09-30; quarterly burn $27.6M; about 48.6 months of runway at that rate (XBRL company facts, accession 0000886163-26-000060).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Jun 2024 | [LIGAND PHARMACEUTICALS INC FDA approval](https://sec-api.dev/companies/lgnd/catalysts) | LGND |  | completed, approved | "Verona's portfolio includes Ohtuvayre, which was approved by the FDA in June 2024 for the maintenance treatment of COPD in adult patients." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/886163/000088616325000047/q22025earningsrelease_ex991.htm)) |
| February 27, 2025 | [LIGAND PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/lgnd/catalysts) | LGND |  | completed | "Ligand Reports Fourth Quarter and Full Year 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/886163/000088616325000008/q42024earningsrelease_ex991.htm)) |
| May 8, 2025 | [LIGAND PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/lgnd/catalysts) | LGND |  | completed | "Ligand Reports First Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/886163/000088616325000033/q12025earningsrelease_ex991.htm)) |
| August 7, 2025 | [LIGAND PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/lgnd/catalysts) | LGND |  | completed | "Ligand Reports Second Quarter 2025 Financial Results and Raises Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/886163/000088616325000047/q22025earningsrelease_ex991.htm)) |
| November 6, 2025 | [LIGAND PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/lgnd/catalysts) | LGND |  | completed | "Ligand Reports Third Quarter 2025 Financial Results and Raises Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/886163/000088616325000058/q32025earningsrelease_ex991.htm)) |
| November 26, 2025 | [FILSPARI (sparsentan) topline data readout](https://sec-api.dev/pdufa/sparsentan) | LGND |  | completed, positive | "•On November 26, 2025, Renalys Pharma, Inc., now Chugai Pharmaceuticals, announced positive topline results from its Phase 3 clinical study of sparsentan, an orally administered dual endothelin and angiotensin II receptor antagonist, in Japanese patients with IgA nephropathy (IgAN)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/886163/000088616326000003/q42025earningsrelease_ex991.htm)) |
| February 26, 2026 | [LIGAND PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/lgnd/catalysts) | LGND |  | completed | "Ligand Reports Fourth Quarter and Full Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/886163/000088616326000003/q42025earningsrelease_ex991.htm)) |
| April 13, 2026 | [Rapamycin PDUFA date](https://sec-api.dev/pdufa/rapamycin) | LGND |  | scheduled | "The new Prescription Drug User Fee Act (PDUFA) target action date is April 13, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/886163/000088616326000003/q42025earningsrelease_ex991.htm)) |
| April 29, 2026 | [Rapamycin PDUFA date](https://sec-api.dev/pdufa/rapamycin) | LGND |  | scheduled | "The target action date for the FDA decision is April 29, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/886163/000088616326000003/q42025earningsrelease_ex991.htm)) |
| May 7, 2026 | [LIGAND PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/lgnd/catalysts) | LGND |  | completed | "Ligand Reports First Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/886163/000088616326000030/q12026earningsrelease_ex991.htm)) |
| August 6, 2026 | [LIGAND PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/lgnd/catalysts) | LGND |  | completed | "Ligand Reports Second Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/886163/000088616326000041/q22026earningsrelease_ex991.htm)) |
| October 29, 2026 | [LIGAND PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/lgnd/catalysts) | LGND |  | completed | "Ligand Reports Third Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/886163/000088616326000058/q32026earningsrelease_ex991.htm)) |
| 2027 | [ZTALMY (ganaxolone) trial start](https://sec-api.dev/pdufa/ganaxolone) | LGND | refractory status epilepticus | scheduled | "•On October 26, 2026, Immedica announced that it will advance the development of intravenous (IV) ganaxolone for the treatment of refractory status epilepticus (RSE) and plans to initiate a new phase 3 clinical study in 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/886163/000088616326000058/q32026earningsrelease_ex991.htm)) |
| Q2 2027 | [LIGAND PHARMACEUTICALS INC topline data readout](https://sec-api.dev/companies/lgnd/catalysts) | LGND |  | scheduled | "Orchestra BioMed is targeting top line data in the second quarter of 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/886163/000088616326000041/q22026earningsrelease_ex991.htm)) |

## Drugs

- [ZTALMY (ganaxolone)](https://sec-api.dev/pdufa/ganaxolone): refractory status epilepticus

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/lgnd/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "LGND catalysts: LIGAND PHARMACEUTICALS INC PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/lgnd/catalysts

```bibtex
@misc{secapidev_companies_lgnd_catalysts_20261116,
  title        = {LGND catalysts: LIGAND PHARMACEUTICALS INC PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/lgnd/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_lgnd_catalysts_20261116","title":"LGND catalysts: LIGAND PHARMACEUTICALS INC PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/lgnd/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
